[
1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 April 2021. Geneva: World Health Organization; 2021. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19
]Search in Google Scholar
[
2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med.2020; 383:2603–2615.10.1056/NEJMoa2034577
]Search in Google Scholar
[
3. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, FolegattiPM, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397: 99–111.10.1016/S0140-6736(20)32661-1
]Search in Google Scholar
[
4. Reuters. Sinopharm’s COVID-19 vaccine 79% effective, seeks approval in China. https://www.reuters.com/article/us-health-coronavirus-china-vaccine/sinopharms-covid-19-vaccine-79-effective-seeks-approval-in-china-idUSKBN2940C8. 2020.
]Search in Google Scholar
[
5. BBC. Sinovac: Brazil results show Chinese vaccine 50.4% effective. https://www.bbc.com/news/world-latin-america-55642648.2020
]Search in Google Scholar
[
6. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; 586:516-52710.1038/s41586-020-2798-332967006
]Search in Google Scholar
[
7. A.A. North Cyprus completes 1st vaccination drive. https://www.aa.com.tr/en/europe/northern-cyprus-completes-1st-vaccination-drive/2119598 (2021)
]Search in Google Scholar
[
8. Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Al-ford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4.10.1016/j.chom.2021.01.014783983733535027
]Search in Google Scholar
[
9. Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. BioxRviv preprint https://doi.org/10.1101/2021.01.13.426558.2021
]Search in Google Scholar
[
10. Mahase E. Covid-19: Where are we on vaccines and variants? BMJ 2021;372:n597 https://doi.org/10.1136/bmj.n59710.1136/bmj.n59733653708
]Search in Google Scholar
[
11. Beusekom MV. Pfizer, Moderna vaccines may be less effective against B1351 variant. 18 Feb 2021. Center for Infectious Disease Research and Policy, University of Minnesota. https://www.cidrap.umn.edu/news-perspective/2021/02/pfizer-moderna-vaccines-may-be-lesseffective-against-b1351-varian
]Search in Google Scholar
[
12. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v1.
]Search in Google Scholar
[
13. Global Times. Half of Bulgaria’s regions report corona-virus variant first detected in Britain. https://www.global-times.cn/page/202103/1217786.shtml (9 March 2021)
]Search in Google Scholar
[
14. Roquebert B, Haim-Boukobza S, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulonge V, Burrel S, Alizon S, Sofonea MT. SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France. Int J of Inf Dis. 2021;113:12-1410.1016/j.ijid.2021.09.076848400434601145
]Search in Google Scholar
